Search clinical trials for: Maximally tolerated dose

Total 21008 results

Acrotech Biopharma Inc.

Completed

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma

United States
Bayer

Terminated

Dose-escalation Study of Lupartumab Amadotin (BAY1129980)

Neoplasms

United States
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)

Anemia, Sickle Cell

United States
Boehringer Ingelheim

Completed

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Idiopathic Pulmonary Fibrosis

Spain, United Kingdom, Italy, Belgium, Germany, Netherlands, Finland, Denmark
Shin Kong Wu Ho-Su Memorial Hospital

Completed

The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC

Advanced Hepatocellular Carcinoma (HCC)

Taiwan
The Cooper Health System

Terminated

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
Henlix, Inc

Completed

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Solid Tumour

Taiwan, United States
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
M.D. Anderson Cancer Center

Completed

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Leukemia

United States
AbbVie

Terminated

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Cancer

United States
Ipsen

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Acromegaly

France, Germany, Spain, Belgium, Russian Federation, United Kingdom, Italy, Lithuania, Czechia, Romania, Poland, Netherlands
Nur Aishah Mohd Taib
Malaysia Palm Oil Board

Unknown

Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer (Matriac)

Breast Cancer Female

Malaysia
Pfizer

Terminated

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

Intracerebral Hemorrhage

Spain, United States, Canada, United Kingdom
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
AbbVie

Terminated

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Breast Cancer

United States
St. Jude Children's Research Hospital

Terminated

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Merck Sharp & Dohme LLC

Completed

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

Depression
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Advanced Malignant Solid Tumors
EMD Serono

Completed

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Solid Tumor

United States
Boehringer Ingelheim

Completed

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Neoplasms | Leukemia

Germany, France, Italy, Belgium, Czechia
Boehringer Ingelheim

Completed

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Korea, Republic of, Japan
National Cancer Institute (NCI)

Completed

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Solid Tumors | Brain Tumors | Brain Metastases

United States
Wake Forest University Health Sciences

Completed

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Advanced Hematologic Malignancies

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Hypercholesterolaemia

Belgium, Spain, Germany, Austria, Italy, United States, France, Netherlands, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
AbbVie

Terminated

A Study of SC-007 in Subjects With Advanced Cancer

Gastric Cancer | Colorectal Cancer (CRC)

United States
National Cancer Institute (NCI)

Terminated

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

Sarcoma | Ewing Sarcoma

United States
Holy Cross Hospital, Florida

Terminated

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

Non-Small-Cell Lung Carcinoma

United States
Mersana Therapeutics

Completed

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
Mersana Therapeutics

Completed

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors (XMT-1107)

Neoplasm Metastasis

United States
National Cancer Institute (NCI)

Completed

Cancer Vaccine Targeting Brachyury Protein in Tumors

Neoplasms | Adenocarcinoma | Colon Neoplasms | Malignant Solid Tumors

United States
Peking University People's Hospital

Unknown

The Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical Cord

Knee Osteoarthritis | Umbilical Cord Bleeding
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms

United States
GlaxoSmithKline

Completed

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Substance Dependence

United Kingdom
National Cancer Institute (NCI)

Completed

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Sarcoma | Lymphoma | Neuroblastoma | WilmsTumor

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Sarcoma | Lymphoma | Brain Neoplasms | Osteosarcoma | Wilm's Tumor

United States
National Cancer Institute (NCI)

Withdrawn

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Sarcoma | Osteosarcoma | Brain Tumor | Neuroblastoma | Wilms Tumor

United States
National Cancer Institute (NCI)

Withdrawn

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Glioma | Pinealoma | Brain Stem Neoplasms
Onconova Therapeutics, Inc.

Completed

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Advanced Solid Tumors

United States
Newron Pharmaceuticals SPA

Completed

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Schizophrenia

United States
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Completed

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer

3

Subscribe